Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.50 |
| ▸ | GABRP | O00591 | 1/20 | 0.50 |
| ▸ | GABRD | O14764 | 1/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.50 |
| ▸ | GABRE | P78334 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.50 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.50 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30948754 | 0.87 | KMT2A (0.48) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL730807 | 0.83 | TDP1 (0.38) | NOS2CYP2D6KMT2AKDM4EMAPT | |
| SCHEMBL543402 | 0.83 | — | — | |
| SCHEMBL2351082 | 0.79 | TSHR (0.58) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL4743865 | 0.78 | — | — | |
| SCHEMBL532571 | 0.78 | CES2 (0.43) | TSHRNOS2CYP2D6KMT2AKDM4E | |
| SCHEMBL21573965 | 0.77 | TSHR (0.50) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL3114031 | 0.76 | CES2 (0.48) | TSHRNOS2CYP2D6KMT2AKDM4E | |
| SCHEMBL4079495 | 0.76 | CES2 (0.48) | TSHRNOS2CYP2D6KMT2AKDM4E | |
| SCHEMBL163416 | 0.76 | CES2 (0.48) | TSHRNOS2CYP2D6KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048633-A1 | Piperidine-4-acrylamides | LEHR PHILIPP | 2010-02-25 | — | — | US | disclosed |
| US-20100048633-A1 | Piperidine-4-acrylamides | LEHR PHILIPP | 2010-02-25 | — | — | US | disclosed |
| CN-101600693-A | The piperidin-acetamide derivatives that is used for the treatment of inflammatory or anaphylactic disease | NOVARTIS AG (CH) | 2009-12-09 | — | — | CN | disclosed |
| EP-2125731-A1 | PIPERIDIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC DISEASES | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008092844-A1 | PIPERIDIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC DISEASES | NOVARTIS AG (CH) | 2008-08-07 | — | — | WO | disclosed |
| WO-2006071035-A1 | NOVEL ([1,3]THIAZOLO[5,4-B]PYRIDIN-2-YL)-2-CARBOXAMIDE DERIVATIVES | LG LIFE SCIENCES, LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048633-A1 | Piperidine-4-acrylamides | CCR3, CCR1, CCR4 | GABRA1 1814/4885TSHR 2900/4885GABRG2 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.